GRAFT VERSUS HOST DISEASE

This study is a long-term safety follow-up for patients who have already been treated with the drugs ruxolitinib or ruxolitinib plus panobinostat in previous Novartis or Incyte trials. It allows patients who are still benefiting from the treatment to continue receiving it while r…

This study is testing a method to process stem cell transplants for patients with a serious blood disorder called myelodysplastic syndrome (MDS). The goal is to reduce a common and dangerous complication called graft-versus-host disease (GVHD), where the donor's immune cells atta…

This study is testing whether using lower doses of a key drug (cyclophosphamide) and for a shorter time after a stem cell transplant can reduce side effects while still preventing a dangerous complication called graft-versus-host disease (GVHD). It involves people ages 15-65 with…

This study is testing if giving more doses of a drug called abatacept can better prevent a dangerous complication called graft-versus-host disease (GVHD) in children and teens. The trial includes 30 young patients with serious non-cancerous blood diseases who are receiving a stem…

This study is testing whether a lower-dose combination of medications can safely prevent graft-versus-host disease (GVHD) in older adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body, and current prevention metho…

This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells atta…

This study aims to understand if changes in a patient's gut bacteria and the chemicals they produce are linked to a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant. Researchers will collect stool and blood samples from 88 transplant patie…